Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.71 |
| ▸ | P4HB | P07237 | 12/20 | 0.55 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16226328 | 0.92 | ACHE (0.63) | ACHEMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL7328357 | 0.91 | ACHE (0.61) | ACHEP4HBSMAD3OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL7440651 | 0.91 | ACHE (0.61) | ACHEMEN1PKMKMT2AOPRM1 | |
| SCHEMBL16225811 | 0.84 | ACHE (1.00) | ACHEMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL7427630 | 0.81 | CYP2D6 (0.59) | ACHEP4HBMEN1KMT2AOPRM1 | |
| SCHEMBL16226434 | 0.81 | ACHE (1.00) | ACHEMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL8802768 | 0.81 | ACHE (0.56) | ACHEMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL23565685 | 0.79 | ACHE (0.49) | ACHEP4HBSMAD3 | |
| SCHEMBL336219 | 0.79 | CYP2D6 (0.67) | ACHEP4HBMEN1KMT2AOPRM1 | |
| SCHEMBL3184987 | 0.79 | ACHE (0.54) | ACHEMEN1KMT2AOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-8653268-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130190496-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2013-07-25 | — | — | US | disclosed |
| US-8367826-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120077979-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-03-29 | — | — | US | disclosed |
| US-20080027110-A1 | Indolyl-3-glyoxylic acid derivatives having antitumor action | ASTA MEDICA AKTIENGESELLSCHAFT | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077979-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | ACHE 2438/4885P4HB 2779/4885SMAD3 1234/4885 |
| US-20130190496-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | ACHE 2438/4885P4HB 2779/4885SMAD3 1234/4885 |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | ACHE 1285/4885P4HB 1749/4885SMAD3 3013/4885 |
| US-20080027110-A1 | Indolyl-3-glyoxylic acid derivatives having antitumor action | IDO1, IDO2, TDO2 | ACHE 2320/4885P4HB 3498/4885SMAD3 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.